Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aplidin in Advanced Prostate Cancer
NCT00780975Phase 2Terminated
- Sponsor
- PharmaMar
- Start
- Feb 2005
- Primary completion
- Mar 2008
- Modality
- Cyclic Peptides, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of plitidepsin in prostate adenocarcinoma, sponsored by PharmaMar. Primary endpoint: Percentage of Patients With a >= 50% Prostate-specific Antigen (PSA) Decline Post-therapy up to 1 year. Started Feb 2005; status: terminated.
02
Drugs
plitidepsin
03
Conditions
prostate adenocarcinoma
Beyond the preview
Go deeper on NCT00780975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00780975.